Abstract
Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anti-cancer therapy. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two classes of enzymes regulating histone acetylation and whose altered activity has been identified in several cancers. In particular, imbalance in histone acetylation can lead to changes in chromatin structure and transcriptional dysregulation of genes that are involved in the control of proliferation, cell-cycle progression, differentiation and/or apoptosis. In addition, several non histone protein substrates such as transcription factors, chaperone proteins or tubulin, undergo acetylation as key post-translation modification regulating their half-life and function. On this regard, several inhibitors of HDAC, selected by academic as well as industrial research, have been recently shown to induce growth arrest and apoptosis in a variety of human cancer cells and have been patented as anti-cancer agents. Although several clinical studies with HDAC inhibitors are ongoing, their mechanism of action cannot be solely attributed to the level of histone acetylation and molecular basis for their tumor selectivity remains unknown, presenting a challenge for the cancer research community.
Keywords: Histone deacetylase, histone deacetylase inhibitors, combination therapy, cancer
Recent Patents on Anti-Cancer Drug Discovery
Title: Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Volume: 2 Issue: 2
Author(s): Alfredo Budillon, Elena Di Gennaro, Francesca Bruzzese, Monia Rocco, Giuseppe Manzo and Michele Caraglia
Affiliation:
Keywords: Histone deacetylase, histone deacetylase inhibitors, combination therapy, cancer
Abstract: Epigenetics as well as post-translational modifications of proteins are emerging as novel attractive targets for anti-cancer therapy. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two classes of enzymes regulating histone acetylation and whose altered activity has been identified in several cancers. In particular, imbalance in histone acetylation can lead to changes in chromatin structure and transcriptional dysregulation of genes that are involved in the control of proliferation, cell-cycle progression, differentiation and/or apoptosis. In addition, several non histone protein substrates such as transcription factors, chaperone proteins or tubulin, undergo acetylation as key post-translation modification regulating their half-life and function. On this regard, several inhibitors of HDAC, selected by academic as well as industrial research, have been recently shown to induce growth arrest and apoptosis in a variety of human cancer cells and have been patented as anti-cancer agents. Although several clinical studies with HDAC inhibitors are ongoing, their mechanism of action cannot be solely attributed to the level of histone acetylation and molecular basis for their tumor selectivity remains unknown, presenting a challenge for the cancer research community.
Export Options
About this article
Cite this article as:
Alfredo Budillon , Elena Di Gennaro , Francesca Bruzzese , Monia Rocco , Giuseppe Manzo and Michele Caraglia , Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (2) . https://dx.doi.org/10.2174/157489207780832450
DOI https://dx.doi.org/10.2174/157489207780832450 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Mentha L. Species (Lamiaceae) as Promising Sources of Bioactive Secondary Metabolites
Current Pharmaceutical Design Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Novel Oral Anticoagulants in the Management of Polycythemia Vera and Essential Thrombocythemia
Cardiovascular & Hematological Agents in Medicinal Chemistry DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics
Current Cancer Drug Targets Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design Metallothioneins and Cancer
Current Protein & Peptide Science The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review
Current Drug Safety Qigefang Inhibits Migration, Invasion, and Metastasis of ESCC by Inhibiting Gas6/Axl Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery